These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Problems in the current target therapy of malignancies]. Stukov AN; Gershanovich ML; Filov VA; Imianitov EN Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022 [No Abstract] [Full Text] [Related]
7. Targeting tyrosine kinases in cancer: the second wave. Baselga J Science; 2006 May; 312(5777):1175-8. PubMed ID: 16728632 [TBL] [Abstract][Full Text] [Related]
8. Protein kinases as drug targets in cancer. Arslan MA; Kutuk O; Basaga H Curr Cancer Drug Targets; 2006 Nov; 6(7):623-34. PubMed ID: 17100568 [TBL] [Abstract][Full Text] [Related]
10. Type II kinase inhibitors: an opportunity in cancer for rational design. Blanc J; Geney R; Menet C Anticancer Agents Med Chem; 2013 Jun; 13(5):731-47. PubMed ID: 23094911 [TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives]. Grimm CF; Blum HE; Geissler M Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020 [No Abstract] [Full Text] [Related]
17. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments. Dear R; Wilcken N; Shannon J Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753 [TBL] [Abstract][Full Text] [Related]
18. [Kinase inhibitors]. Yamori T; Kong D Nihon Rinsho; 2010 Jun; 68(6):1059-66. PubMed ID: 20535956 [TBL] [Abstract][Full Text] [Related]
19. New insights into oncogene addiction found. Garber K J Natl Cancer Inst; 2007 Feb; 99(4):264-5, 269. PubMed ID: 17312299 [No Abstract] [Full Text] [Related]
20. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Kim R; Toge T Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]